

# Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020

<https://marketpublishers.com/r/CD4C7D5E3B59EN.html>

Date: October 2020

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: CD4C7D5E3B59EN

## Abstracts

Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020

### SUMMARY

According to the recently published report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020'; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein is a plasma protein that promotes the transfer of cholesteryl esters from anti-atherogenic HDLs to proatherogenic apolipoprotein B (apoB)-containing lipoproteins, including VLDLs, VLDL remnants, IDLs, and LDLs. A deficiency of CETP is associated with increased HDL levels and decreased LDL levels, a profile that is typically anti-atherogenic.

The report 'Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020' outlays comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Cardiovascular which include indications Dyslipidemia, Acute Coronary Syndrome and

Cardiovascular Disease.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects

The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Overview

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics  
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics  
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies  
Involved in Therapeutics Development

Bristol-Myers Squibb Co

Chong Kun Dang Pharmaceutical Corp

DalCor Pharmaceuticals Inc

NewAmsterdam Pharma BV

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles

CKD-508 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CKD-519 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalcetrapib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-16 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obicetrapib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CETP for Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CETP for Dyslipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Product Development Milestones

Featured News & Press Releases

Jul 27, 2020: DalCor announces dal-GenE trial continues with final data expected in the first half of 2021

Jan 27, 2020: Dalcor announces Dal-gene trial to continue as planned following interim futility analysis

Dec 17, 2018: Dalcor announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease

Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile

Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial

Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE

## Phase 3 Cardiovascular Outcomes Trial

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet

Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease

Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Bristol-Myers Squibb Co, H2 2020

Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020

Pipeline by DalCor Pharmaceuticals Inc, H2 2020

Pipeline by NewAmsterdam Pharma BV, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

Discontinued Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020 (Contd..2), H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020



## I would like to order

Product name: Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/CD4C7D5E3B59EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CD4C7D5E3B59EN.html>